Best Medications and Doses for Acute Gout Flare
For an acute gout flare, use corticosteroids (prednisolone 35 mg daily for 5 days), NSAIDs (any NSAID at maximum dose), or low-dose colchicine (1.2 mg followed by 0.6 mg one hour later), with corticosteroids preferred as first-line due to superior safety profile and equal efficacy. 1
First-Line Treatment Options
The 2017 American College of Physicians guideline provides strong, high-quality evidence that three medication classes are equally effective for acute gout 1:
Corticosteroids (Preferred First-Line)
- Dose: Prednisolone 35 mg daily for 5 days 1
- Safest option with fewer adverse effects than NSAIDs
- As effective as NSAIDs for pain relief
- Contraindications: Systemic fungal infections
- Cautions: Short-term use minimizes risks of dysphoria, hyperglycemia, immune suppression, and fluid retention
NSAIDs (Alternative First-Line)
- Any NSAID at maximum recommended dose - no evidence that indomethacin is superior to naproxen or ibuprofen 1
- Examples: Ibuprofen 2400 mg/day 2, Etoricoxib 120 mg daily 3
- Contraindications: Renal disease, heart failure, cirrhosis
- Adverse effects: Dyspepsia, GI bleeding, ulcers
Colchicine (Alternative First-Line)
- Dose: 1.2 mg followed by 0.6 mg one hour later, then 0.5 mg 2-3 times daily 1, 4
- Low-dose regimen equally effective as high-dose with significantly fewer GI side effects
- Critical timing: Must start within 12 hours of symptom onset for optimal efficacy 4
- Dose reduction required: Chronic kidney disease, concurrent CYP3A4 inhibitors or P-glycoprotein inhibitors
- Contraindications: Renal/hepatic impairment with potent drug interactions
- First sign of toxicity: Diarrhea - reduce dose immediately 4
- More expensive than corticosteroids or NSAIDs 1
COX-2 Selective Inhibitors vs Non-Selective NSAIDs
Moderate-quality evidence shows COXIBs and traditional NSAIDs provide equivalent pain relief and functional improvement, but COXIBs cause significantly fewer total adverse events (38% vs 60%) and fewer withdrawals due to adverse events (3% vs 8%) 5. Consider COXIBs when GI safety is a concern.
Corticosteroids vs NSAIDs Head-to-Head
Moderate-quality evidence demonstrates no difference in pain reduction or function between oral glucocorticoids and NSAIDs, with similar total adverse event rates 5. This supports corticosteroids as the preferred first-line option given their lower cost and generally safer profile.
Critical Treatment Principles
Early treatment is essential - patients should be educated to self-medicate within 12 hours of flare onset using a pre-defined treatment plan 4. The French Society of Rheumatology emphasizes this as an overarching principle.
Screen for contraindications carefully before selecting therapy:
- Renal function (affects NSAIDs, colchicine dosing)
- Cardiovascular disease (affects NSAIDs, COXIBs)
- Drug interactions (critical for colchicine)
- Infection risk (affects corticosteroids)
- GI bleeding history (affects NSAIDs)
Second-Line Options
IL-1 inhibitors (anakinra, canakinumab) are reserved for patients who fail, cannot tolerate, or have contraindications to all three first-line options 4, 6. They require monitoring for infection and neutropenia.
Common Pitfalls to Avoid
- Don't delay treatment - efficacy decreases significantly after 12 hours 4
- Don't use high-dose colchicine - the traditional 1.2 mg followed by 0.6 mg hourly regimen causes unnecessary GI toxicity without added benefit 1
- Don't assume indomethacin is superior - any NSAID works equally well 1
- Don't forget dose adjustment - colchicine requires reduction in CKD and with interacting medications 4
- Don't stop urate-lowering therapy if already taking it - continue during the flare 7